Corbus Pharmaceuticals
Présence
Corbus Pharmaceuticals est une société cotée sous le symbole boursier CRBP (US).
Dirigeants
Voir l'organigramme avec ses 13 principaux dirigeants
Biographies les plus recherchées chez Corbus Pharmaceuticals
- Yuval Cohen, Chief Executive Officer and Director
- Alan Holmer, Chairman of the Board
- Yong Ben, Director
Changements de dirigeants chez Corbus Pharmaceuticals
- Dominic Smethurst, a rejoint l'entreprise comme Chief Medical Officer (publié le 1 mars 2024).
Créer une alerte
pour suivre les mouvements de dirigeants chez Corbus Pharmaceuticals.
Pharmacie
Corbus Pharmaceuticals a 1 861 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Johnson & Johnson (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- MedMen has filed for bankruptcy protection (publié le 28 avril 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publié le 23 mars 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publié le 19 mars 2024).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Corbus Pharmaceuticals
- Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
- Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
- Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
- Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
- Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
- Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Corbus Pharmaceuticals Announces Proposed Public Offering
- Corbus Pharmaceuticals Announces Pricing of Public Offering
- Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
- CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Corbus Pharmaceuticals
- Corbus Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Corbus Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont Yuval Cohen 
Appelez Corbus Pharmaceuticals au +1 617...
